Universal Health: Bears Have Taken It Too Far - 134% Upside

Bashar Issa 7.92K Followers Follow Summary Universal Health Services, Inc. is rated Strong Buy due to undervaluation at 8x forward P/E and resilient earnings growth. Recent guidance cuts reflect mostly temporary challenges, with consolidated revenue and EBITDA still growing across both Acute Care and Behavioral Health segments. Medicaid reimbursement cuts are gradual and manageable, with management repositioning toward outpatient behavioral health and private payors. A nearly $1 billion share buyback and potential multiple expansion to sector median support a price target for UHS of $428/share. Investment Thesis Universal Health Services, Inc. ( UHS ) shares have come under pressure after some of its newly opened hospitals generated losses for longer than expected. The company cut FY'26 guidance. In the medium term, Medicaid cuts and other public This article was written by Bashar Issa 7.92K Followers Follow Bashar is a financial analyst writing on Seeking Alpha, focused on growth stocks, contrarian setups, and market mispricing. His research looks for companies where consensus is missing a shift in earnings power, competitive positioning, or industry structure. Bashar does not invest personally in the stocks he covers. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.